CI

At a glance

ClinicalIndex Comparison Record
Phase 1Recruiting· 20 target
Drug / intervention
TCR-MAGE-A4 T-Cellsdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06170294
NCT06170294Phase 1RecruitingUpdate OverdueUpdated 30mo ago · Completion was 6mo ago
Enrollment Stalled
Update Overdue
CompareCT.gov

A Single-arm, Open-label, Dose Exploratory Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Autologous Humanized MAGE-A4-directed T Cell Receptor Engineered T Cell (JWTCR001) in Patients With Advanced Solid Tumors

Peking University·interventional·Posted Dec 14, 2023·Updated Dec 14, 2023

In Brief

A Phase 1 clinical trial evaluating TCR-MAGE-A4 T-Cells for Advanced Solid Tumor. Currently recruiting, targeting 20 participants across 1 site.

Signals

Enrollment appears stalled

Detailed Summary

A single-arm, open-label, dose exploratory study to evaluate the safety, efficacy, and pharmacokinetics of autologous humanized anti-MAGE-A4 T cell receptor-engineered T cell (TCR-T) in advanced solid tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumor
CountriesChina
CollaboratorsShanghai Ming Ju Biotechnology Co., Ltd.

Timeline

Phase 1Recruiting
202420252026202720282029
First PostedDec 14, 2023
Enrollment StartJan 1, 2024
Primary CompletionDec 31, 2025
Study CompletionDec 31, 2028
TodayJul 1, 2026
Enrollment to primary: 2 yearsPosted 2.5 years ago

Interventions

TCR-MAGE-A4 T-Cellsdrug

* Preconditioning with fludarabine, cyclophosphamide, based chemotherapy regimen at sub-clinical doses * MAGE-A4-directed T cell receptor-engineered T Cells